Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Anti-InflammatoryEnrolling Location: Multiple care centres across the US

    Phase 2 study of LAU-7b in adults with CF (APPLAUD) , protocol number NCT03265288

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug LAU-7b and it will use a placebo control.

    • Age:

      12 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      50-90%

    • Number of Visits:

      6

    • Length of Participation:

      189 days

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    OPTIMISE: Phase 3 study of tobramycin solution for inhalation with and without azithromycin , protocol number OPTIMISE-IP-12

    This study is taking place at multiple care centers across the US. It will compare the effects of treatment with tobramycin solution for inhalation with and without azithromycin. It is for people with CF who have their first isolation of Pseudomonas aeruginosa from a respiratory culture.

    • Age:

      6 Months to 18 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      8

    • Length of Participation:

      18 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    Phase 1b safety study of QR-010 in adults with CF , protocol number NCT02532764 PQ-101-001

    This study is taking place at multiple care centers across the U.S. It will test the safety and tolerability of the drug QR-010 in adults with cystic fibrosis. It will also look at how the body processes the drug..

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      60 to 90%

    • Number of Visits:

      9

    • Length of Participation:

      28 days

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: USA

    PROSPECT , protocol number PROSPECT-OB-14

    This two-part study is taking place at multiple care centres across the US. It will aim to identify biomarkers that show CFTR function and disease progression. It will also look at the effect of lumacafter/ivacaftor on those who are prescribed treatment.

    • Age:

      6 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      8

    • Length of Participation:

      15 months

    Contact us about this clinical Trial >
  • Mucociliary ClearanceClosed to enrollment Location: USA

    Clearing Lungs With ENAC Inhibition in Cystic Fibrosis (CLEAN-CF) , protocol number Parion PS-G201

    This trail will look at the safety of the drug P-1037 and its effectiveness in combination with the drug hypertonic saline. The trail is estimated to last 5 weeks. It is for people with CF age 12 years and older.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      4

    • Length of Participation:

      5 weeks

    Contact us about this clinical Trial >
  • Anti-InfectiveClosed to enrollment Location: USA

    AeroVanc for the treatment of MRSA in people with CF , protocol number Savara SAV005-02

    This study took place at multiple care centres across the US. It looked at the safety and effectiveness of AeroVanc in treating persistent MRSA lung infections in people with cystic fibrosis.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      30 to 100%

    • Number of Visits:

      9

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • Mucociliary ClearanceEnrolling Location: USA

    SHIP: Study of hypertonic saline in preschoolers , protocol number SHIP01 NCT02378467

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of hypertonic saline compared to isotonic saline (normal saline) in children with CF.

    • Age:

      3 Years to 5 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      Less than 99%

    • Number of Visits:

      6

    • Length of Participation:

      54 weeks

    Contact us about this clinical Trial >
  • Anti-InflammatoryCompleted with results Location: USA

    Phase 2 Study of inhaled Alpha-1 HC in people with CF , protocol number Grifols T6005-201

    This study took place at multiple care centres across the US. It looked at the safety and tolerability of inhaled Alpha-1 HC administered once a day for three weeks in people with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      5

    • Length of Participation:

      9 weeks

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    Phase 2 Study of Inhaled Nitric Oxide in People with CF , protocol number NCT02498535

    This study is taking place at multiple care centres across the US. It will look at the effectiveness of the inhaled drug nitric oxide in adults with cystic fibrosis who are taking an inhaled antibiotic.

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      35-85%

    • Number of Visits:

      10

    • Length of Participation:

      43 days

    Contact us about this clinical Trial >
  • Nutritional-GIEnrolling Location: USA

    Phase 2 study of oral glutathione in children with cystic fibrosis. , protocol number NCT03020719

    This study is taking place at multiple care centres across the USA. It will look at the safety and effectiveness of the oral drug glutathione in children wit cystic fibrosis.

    • Age:

      24 months - 10 years

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      4

    • Length of Participation:

      6 months

    Contact us about this clinical Trial >
  • Displaying results 111-120 (of 142)
     |<  <  6 - 7 - 8 - 9 - 10 - 11 - 12 - 13 - 14 - 15  >  >|